Effects of the Gonadotropin-Releasing Hormone Agonist [D-LEU 6 , Desgly-NH2 10 , Proethylamide 9 ]-GnRH (Leuprolide) on R3327-G Rat Prostatic Tumor Growth

Publisher Website
Google Scholar
Abstract
The synthetic gonadotropin releasing hormone agonist [D-leu6,desgly-NH210, proethylamide9]-GnRH [gonadotropin-releasing hormone] (leuprolide) was tested for its ability to inhibit androgen-sensitive R3327-G rat prostatic tumor growth in Copenhagen .times. Fischer F1 male rats. The chronic administration of leuprolide at 50 .mu.g/kg body wt or 1000 .mu.g/kg body wt significantly reduced serum testosterone levels and testis weights. Only chronic leuprolide administration at high concentration (1000 .mu.g/kg) compared with orchiectomy in reducing the rate of tumor growth, prolonging survival, and affecting changes in DNA content per cell as quantitated by flow cytometry. The DNA content changes and cell kinetic responses of R3327-G tumors to these treatments were related to the extent to which serum testosterone levels were reduced. For some [human] prostatic cancers GnRH agonist administration must reduce serum testosterone levels to those achieved by orchiectomy for maximal growth rate inhibition.

This publication has 14 references indexed in Scilit: